National. Screening Report Deutsche Gesellschaft für Neugeborenenscreening DGNS
|
|
- Marion Myrtle Bailey
- 6 years ago
- Views:
Transcription
1 National Report 2007 Deutsche Gesellschaft für Neugeborenenscreening DGNS Dr. med. Uta Nennstiel-Ratzel MPH, Dr. med. Anja Lüders MPH, Dr. med. Oliver Blankenstein, Dr. rer. nat. Uta Ceglarek, Dr. med. Regina Ensenauer, Dr. rer. nat. Ralph Fingerhut, Dr. rer. nat. Jeannette Klein, Dr. med. Martin Lindner, Dr. rer. nat. Cornelia Müller, PD Dr. med. Michael Peter, Prof. Dr. med. Ernst Rauterberg, Inge Schneider, Dr. med. Dr. rer. nat. Wolfgang Schultis, Prof. Dr. med. Andreas Schulze, Dipl.-Biochem. Irmgard Starke, Dipl. Ing. Maren Stehn, Dr. rer. nat. Marina Stopsack, Prof. Dr. med. Christoph Fusch
2 Contents 1 Introduction Laboratories and Centres Results Data of primary screening Relation of requested to received repeat screenings Tracking of completeness of screening Requirements to a repeat screening card due to bad sample quality Recall Rate, Prevalence, Positive predictive value specificity Recall rate, prevalence stratified Recall rate stratified according to age of primary screening Process Periods Age at blood collection Period from sampling to laboratory receipt Period between laboratory receipt and conveyance Time of screening in the confirmed cases screening Indication for request of repeat testing in the confirmed cases Confirmation of pathological results Organisation Acquisition of completeness Tracking Methods and cut offs in screening Filter paper for sampling Hypothyroidism Biotinidase Deficiency Galactosaemia MS/MS Congenital adrenal hyperplasia (CAH) MS/MS Parameter Literature...49 DGNS-Report 2007 Page 2 of 49
3 Figures Figure 1: Distribution of analysis according to county and laboratory... 6 Figure 2: Comparison: Age at blood collection 2005 and Figure 3: Period between sampling and laboratory receipt: Comparison 2005 to Figure 4: Period from laboratory receipt to conveyance, comparison of 2005 to Figure 5: Time elapsed from initiation of therapy in children with hypothyroidism (n=129) Figure 6: Time elapsed from initiation of therapy in children with CAH (n=44) Figure 7: Time elapsed from initiation of therapy in children with PKU (n=50) Abbreviations: CAH CACT- Deficiency CPTI- Deficiency CPTII- Deficiency GA I BW HPA IVA Congenital adrenal hyperplasia Carnitin-Acylcarnitin-Translocase-Deficiency Carnitin- Palmitoyl-CoA-Transferase I-Deficiency Carnitin- Palmitoyl-CoA-Transferase II-Deficiency Glutaric acidaemia type I Birth weight Hyperphenylalaninaemia Isovaleric acidaemia LCHAD-Deficiency Long-Chain-3-hydroxy-Acyl-CoA-Dehydrogenase-Deficiency DoL Day of life GV 1-3 guide value 1-3 MCAD-Deficiency MSUD NBS SP PKU PPV WoG Medium-Chain-Acyl-CoA-Dehydrogenase-Deficiency Maple syrup urine disease New born screening secondary parameter Phenylketonuria positive predictive value Week of gestation VLCAD-Deficiency Very-Long-Chain-Acyl-CoA-Dehydrogenase-Deficiency DGNS-Report 2007 Page 3 of 49
4 1 Introduction The newborn screening is a medical population based preventative measure with the aim of early and sufficient detection and high quality therapy of all newborns with treatable endocrine or metabolic diseases. The guidelines of prevention of disease for children up to 6 years of age ( Kinder-Richtlinien ) outline the details of newborn screening (NBS) since The National Report 2007 was composed by the Deutschen Gesellschaft für Neugeborenenscreening (DGNS e.v.) as well as the German screening laboratories. The statistical analysis of the screening data was according to the guidelines and their quality criteria of the NBS implementation. This report targets only the metabolic and endocrine diseases which are defined in these guidelines. It provides a wide statistical summary of disease related screening numbers, recall numbers at diagnoses for the year Additionally, data for process quality are presented. Process quality describes the process flow and its evaluation through specialists according to defined indicators. These are the following for the newborn screening: Total Survey of the population Collection method and rate Blank card system Completeness of the control and the secondary testing Collection of test parameters and cut offs According to laboratory, age as well as gestational age, stratified rates of recall, positive predictive values and prevalence Specificity and sensitivity of diagnostic tests Process times (preanalytic and laboratory), age at blood collection, time within blood collections, time of arrival in the laboratory and time of result communication values of newborns for which further testing is emphasized Diagnostic for confirmation Final diagnosis Start of therapy Type of diagnostic Time of diagnostic In chapter 2, laboratories are listed which have undertaken the screening in 2007 for Germany. From chapter 3 the laboratories are listed scrambled. (see chapter 2 - laboratory number, numbers 12 and 13 relate to the same laboratory, ones with and without the cooperation of the Centre, same for 14 and 15). Paragraphs in the text relate to the altered guidelines for children from 21/12/04 (1). Tables are numbered according to the chapters. We thank all the laboratories for provision of their data. The data was checked for plausibility. Finally, the provided, and if necessary corrected, data was analysed. Remaining inconsistencies of data was analysed according to the reported data. (Inconsistency partly due to the system). DGNS-Report 2007 Page 4 of 49
5 2 Laboratories and Centres Centers (laboratories) with different localities or laboratories which are connected to a screening centre are analysised stratified. 1) Neugeborenen labor Berlin Dr. med. Oliver Blankenstein Augustenburger Platz Berlin 030/ Oliver.Blankenstein@charite.de zentrum Sachsen 3) Standort Dresden Prof. Dr. med. Joachim Thiery, Universitätsklinikum Leipzig Standort Dresden PF Dresden 0351/ / 5229 marina.stopsack@uniklinikum-dresden.de 10) Standort Leipzig Paul-Listr-Str Leipzig 0341/ (Leitstelle ILM) uta.ceglarek@medizin.uni-leipzig.de 5) -Zentrum Hessen Prof. Dr. med. Ernst W. Rauterberg Feulgenstr Giessen 0641/ ernst.w.rauterberg@paediat.med.uni-giessen.de 6) Neugeborenenscreeninglabor M-V Prof. Dr. med. Christoph Fusch Soldmannstr Greifswald 03834/ fusch@uni-greifswald.de greifswald.de/kind_med/neugeborenscreening- Dateien/slide0001.htm 7) -Labor, Universitätskinderklinik Prof. Dr. med. René Santer Martinistr Hamburg 040/ r.santer@uke.uni-hamburg.de 8) -Labor Hannover Prof. Dr. med. J. Sander, PD Dr. med. M. Peter Postfach D Hannover 05108/ j.sander@metabscreen.de, m.peter@metabscreen.de 9) Neugeborenenscreening Heidelberg Prof. Dr. med. G.F. Hoffmann Im Neuenheimer Feld Heidelberg 06221/ martin.lindner@med.uni-heidelberg.de 11) labor, Universitäts-Kinderklinik Dipl.-Biochem. Irmgard Starke PSF Magdeburg 0391/ irmgard.starke@med.ovgu.de 13) Labor Becker, Olgemöller & Kollegen Prof. Dr. med. Dr. rer. nat. Bernhard Olgemöller Ottobrunner Str München 089/ Olgemoeller@labor-bo.de 15) Medizinisches Versorgungszentrum für Laboratoriumsmedizin u. Mikrobiologie Dr. med. Dr. rer. nat. Hans-Wolfgang Schultis Zur Kesselschmiede Weiden 0961/309 0 schultis@synlab.de zentrum Bayern (12/14) Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit Dr. med. Uta Nennstiel-Ratzel MPH Veterinärstr Oberschleißheim 089/ screening@lgl.bayern.de neugeborenenscreening.htm 12) Labor Becker, Olgemöller & Kollegen See 13 14) Medizinisches Versorgungszentrum für Laboratoriumsmedizin u. Mikrobiologie See 15 DGNS-Report 2007 Page 5 of 49
6 The screening samples of the federal states are spread to the laboratories according to Figure1. Figure 1: Distribution of analysis according to county and laboratory DGNS-Report 2007 Page 6 of 49
7 3 Results 2007 In the year 2007, children were born in Germany. The total recorded screening exceeds this number slightly at The reason is because a second screening card is recorded as the first screening, as some cards are sent to a different laboratory than the original. A secure statement about the rate of taking part in NGS can only be made by comparison of person related data or the population. By law this is only legal in the country of Bavaria. The screening rate for Germany is 100,3%. Births: First screening: Final diagnosis (see Table 3): 465 In the German guidelines the targeted diseases are defined for the nationwide screening. Some laboratories will also screen for scientific purposes. These results will not be addressed in this report. Of newborns one targeted disease according to the guidelines is found. Table 3 shows the prevalence of targeted diseases in the year 2007 in Germany. Table 3. Absolute number of detected diseases found by screening Disease cases Prevalence Hypothyroidism Congenital adrenal hyperplasia (CAH) Biotinidase Deficiency Galactosaemia (Classic) Phenylketonuria (PKU) n=56 / Hyperphenylalaninaemia (HPA) Maple syrup urine disease (MSUD) Medium-Chain-Acyl-CoA-Dehydrogenase (MCAD)-Deficiency 163 1: : : : : : : Long-Chain-3-OH-Acyl-CoA-Dehydrogenase Deficiency 3 1: (LCHAD)- (Very-)Long-Chain-Acyl-CoA-Dehydrogenase (VLCAD)- 8 1: Deficiency Carnitin-Palmitoyl-CoA-Transferase I (CPTI)-Deficiency 0 Carnitin-Palmitoyl-CoA-Transferase II (CPTII)-Deficiency 1 1: Carnitin-Acylcarnitin-Translocase (CACT)-Deficiency 0 Glutaric acidaemia Type I (GA I) 3 1: Isovaleric acidaemia (IVA) 4 1: Total 465 1: DGNS-Report 2007 Page 7 of 49
8 3.1 Data of primary screening According to the guidelines of children, every newborn should be screened before leaving the birth facility. A reliable screening can only be undertaken with blood sampling beyond the completed 32 nd gestational week and 36 th hour of life. A primary screening before the 36 th hour of life or before the completed 32 nd week of gestation should be followed by a repeat screening (Section 8 - paragraph 2.4). The following table shows the stratified results of the primary screening according to age and gestational age. Table 3.1 Age at primary screening 36h and 32WOG <36h and 32WOG <32WOG Total n % n % n % , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,08 406, , ,09 168, , ,50 226, , ,79 5. Total , , , Relation of requested to received repeat screenings In table the repeat screenings are listed stratified according to their base of request defined as: <32WoG : all sample of newborns before 32 WoG, independent of age and result of primary screening <36h : all sample of newborns beyond 32 WoG, but age less than 36h, independent of the result of primary screening Recall: essential repeat testing due to suspicious primary screening at a gestational age > 32 WoG and age > 36h DGNS-Report 2007 Page 8 of 49
9 Table Requested and received repeat screenings a Total b requested Total b Recall received % b requested Recall received % , , d , , , ,05 7 c , , , , , , , , , , Total , ,99 a <36h requested <36h received % <32WOG requested <32WOG received % , , d , , ,67 7 c , , , , , , , , , , Total , ,42 a Other requested e Other received % , , ,92 a 10 and 15 cannot give information b Inclusive secondary screening due to blood transfusion, parenteral nutrition or medication c cannot differentiate secondary screening completely therefore it is not considered for percentage calculation but for calculation of absolute numbers d n received > n requested, therefore no percentage calculation. e secondary screening due to blood transfusion, parenteral nutrition or medication Non listed laboratories have not given information c d DGNS-Report 2007 Page 9 of 49
10 3.3 Tracking of completeness of screening The newborn screening is a measure of public health and should be given to all in Germany born children. To guarantee that the screen is offered to all newborns the tracking of completeness is necessary. For children born in obstetric units, an alignment of the recorded birth number on the screening card along with the recorded birth number of the sending unit would be possible, or if legally allowed, by comparing with data from the birth register. Currently both measures are not undertaken nationwide. To target the tracking of completeness the following rule was included into the guidelines ( 9.6): The obstetric unit should document on a blank test card refusal of screening or death of a neonate. This test card should then be sent to the screening centre. In 2007 the number of received blank cards has risen markedly, as shown in table 3.3. Tracking of completeness cannot be ensured by this measure. Table 3.3 received blank cards/ requested and screened children Blank Cards Received Alignment Blank Cards undertaken Alignment Recorded birth number alignment Birth Register n n n n n.s n.s. Total registration of blank cards was not differentiated according to reason, as some laboratories cannot differentiate or do not register a reason. only information for laboratories who record alignment. DGNS-Report 2007 Page 10 of 49
11 3.4 Requirements to a repeat screening card due to bad sample quality Lab Control requested Control received received/ requested (%) Percentage of unprocessed screening cards/ (%) ,09 0, , , , ,71 0, ,83 0, ,17 0, ,18 0, ,46 0, ,21 0, ,00 0, n.s. n.s. Total ,07 0,48 4 Recall Rate, Prevalence, Positive predictive value specificity The excellence of a test is measured by the sensitivity, the specificity as well as the positive predictive value. In screening, the sensitivity (true-test positives) but more so the specificity (true-test negatives), should be easy to find all diseased and to avoid unnecessary worries and costs. A measure for the specificity in newborn screening is the recall rate. The smaller the recall rate the higher the specificity. The positive predictive value estimates the risk of disease with a positive test result. It depends on the prevalence of the targeted disease. In Table 4 listed epidemiologic numbers concern all screened children independently of age and gestational age. The sensitivity cannot be calculated since the number of screened but undetected children is not recorded systematically. Recall is a necessary follow-up testing due a positive primary screening. DGNS-Report 2007 Page 11 of 49
12 Table 4 Specificity, PPV related to the total number of primary screening tests independent of age and gestational age. Disease Recall Total Recallrate (%) cases PPV (%) Specificity (%) False negative Hypothyroidism , ,98 99,88 0 CAH , ,08 99,24 0 Biotinidase , ,97 99,98 0 Classic Galactosaemia ,06 9 2,11 99,94 0 MS/MS , ,86 99,89 0 Total , ,98 98,93 0 Considering the analysis is only for screening which was taken from neonates older than 32 WOG and older than 36 hours of life the overall PPV is 7,4%, only about 7% of recalled children suffer from the targeted disease. For some diseases the PPV is very high, e.g. for HPA/PKU 56,9%, for MCAD-deficiency 44,6% and for hypothyroidism 26,5%. The range of the PPV in between different laboratories is wide, e.g. hypothyroidism 11%-47%; MCAD-deficiency 12%-96%. More positive predictive values (of screening > 36 hours of life and >32 WoG) are listed in Table 4a which differ from Table 4. Table 4a: Recall PPV with a screening > 36 hours of life and >32 WoG Disease Recall Recallrate(%) cases PPV(%) Specificity 36h(%) Hypothyroidism , ,53 99,94 CAH , ,22 99,44 Biotinidase , ,08 99,98 Classic Galactosaemia ,06 8 1,93 99,94 MS/MS , ,64 99,90 Total , ,44 99,20 Only targeted diseases DGNS-Report 2007 Page 12 of 49
13 4.1 Recall rate, prevalence stratified Recall rates of the following tables as well as PPV are of newborns that were screened > 32 weeks gestational age and 36 hours age. The reference of > 36 hours automatically includes > 32 weeks gestational age. The confirmed diagnosis, confirmed cases and their prevalence relate to the total screening tests, irrespective to age and gestational age. The validation of confirmed cases was tested for plausibility of metabolic diseases by Professor Andreas Schulze and Dr. Regina Ensenauer, for endocrine diseases by Dr. Oliver Blankenstein. Cases with implausible (n=17) or missing data (n=24) as well as cases which did not have the necessary data for validation (n=41) were excluded from analysis. All double cases were included only once. Table 4.1 All targeted diseases Total 36h Recall 36h Recallrate % a cases PPV 36h (%) Prevalenc e Total False negative Disease Hypothyroidis m , ,53 1: CAH , ,22 1: Biotinidase- Deficiency , ,08 1: Classic Galactosaemia ,06 9 1,93 1: PKU/HPA , ,92 1: MSUD ,01 2 2,20 1: MCAD , ,64 1: LCHAD ,01 3 2,08 1: VLCAD ,02 8 5,26 1: CPT I- Deficiency CPT II- Deficiency : CAT-Deficiency GA I ,02 3 2,48 1: IVA ,01 4 4,65 1: Total , ,44 1: a Recall rate recorded only if 0,01% DGNS-Report 2007 Page 13 of 49
14 4.1.1 Hypothyroidism Total Recall Recallrate(%) cases Prevalence , : ,03 2 1: , : ,02 1 1: ,07 4 1: , : , : ,03 7 1: ,02 3 1: , : , : ,04 8 1: Total , : Recall rate recorded only if 0,01% False negative Congenital adrenal hyperplasia (CAH) Total Recall Recallrate(%) cases Prevalence ,33 4 1: ,05 1 1: ,60 3 1: ,40 3 1: ,12 3 1: , : ,25 8 1: ,17 2 1: ,13 1 1: ,25 5 1: ,12 6 1: ,66 2 1: , Total , : Recall rate recorded only if 0,01% False negative DGNS-Report 2007 Page 14 of 49
15 4.1.3 Biotinidase Deficiency Total Recall Recallrate(%) cases Prevalence ,01 1 1: , ,01 1 1: ,02 1 1: ,02 2 1: , : : , , , , , Total , : Recall rate Recorded only if 0,01% Galactosaemia incl. Variants / Classic Lab a Total Recall Recallrate(%) c cases Prevalence , : ,01 1 1: , , b ,05 1 1: ,10 1 1: ,01 2 1: ,02 4 1: , ,02 2 1: ,03 1 1: , , Total , : Classic 9 1: Recall rate Recorded only if 0,01% False negative False negative DGNS-Report 2007 Page 15 of 49
16 4.1.5 MS/MS MS/MS only targeted diseases Total Recall Recallrate(%) cases Prevalence False negative , : ,19 5 1: , : ,20 3 1: , : , : , : ,05 2 1: ,08 6 1: , : , : , : , Total , : Recall rate recorded only if 0,01% PKU / HPA Lab Total Recall Recallrate(%) cases Prevalence False negative , : ,03 2 1: , : ,02 3 1: ,07 8 1: , : , : ,03 1 1: ,02 4 1: , : , : ,03 6 1: Total , : Only PKU Recall rate recorded only if 0,01% 56 1: DGNS-Report 2007 Page 16 of 49
17 MSUD Total Recall Recallrate(%) cases Prevalence , , , , , : , , : , Total ,01 2 1: Recall rate recorded only if 0,01% False negative MCAD-Deficiency Total Recall Recallrate(%) cases Prevalence False negative ,08 5 1: ,06 2 1: ,07 4 1: , , : , : , : ,01 1 1: ,01 2 1: ,01 7 1: ,01 9 1: ,03 5 1: , Total , : Recall rate recorded only if 0,01% DGNS-Report 2007 Page 17 of 49
18 LCHAD-Deficiency Total Recall Recallrate(%) cases Prevalence , , : ,01 1 1: , , Total ,01 3 1: Recall rate recorded only if 0,01% False negative VLCAD-Deficiency Total Recall Recallrate(%) cases Prevalence False negative ,07 1 1: ,03 1 1: , , , : ,05 2 1: ,01 1 1: Total ,02 8 1: Recall rate recorded only if 0,01% DGNS-Report 2007 Page 18 of 49
19 No confirmed cases of CPTI-Deficiency and for CACT-Deficiency CPT II-Deficiency Total Recall Recallrate(%) cases Prevalence : Total , : Recall rate recorded only if 0,01% False negative Glutaric acidaemia Type I Total Recall Recallrate(%) cases Prevalence False negative , , , ,02 1 1: : , : Total ,02 3 1: Recall rate recorded only if 0,01% DGNS-Report 2007 Page 19 of 49
20 Isovaleric acidaemia Total Recall Recallrate(%) cases Prevalence , , , , , : , ,01 1 1: ,02 2 1: Total ,01 4 1: Recall rate recorded only if 0,01% False negative 4.2 Recall rate stratified according to age of primary screening The number of positives, especially false positive screening results and therefore the recall rate depends on age and gestational age. Earlier testing than the 36 th hour of life and a gestational age of <32 weeks increase the risk of false negative and false positive results. Since this is different for the individual diseases we show the recall rate stratified to targeted disease and age / gestational age. Recall rate is recorded only if it exceeds 0,01%. DGNS-Report 2007 Page 20 of 49
21 4.2.1 Hypothyroidism , , , , , , , , , , , , , , , , , , , , , , , , , Total , , ,27 13 cannot differentiate recall rate according to age, therefore we counted all recalls as 36h 36h Recallrate Recall < 36h Recallrate Recall < 32WOG Recallrate Recall Congenital adrenal hyperplasia (CAH) 36h < 36h < 32WOG Recallrate Recall rate Recall rate Recall- Recall- Recall , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,00 Total , , ,67 13 cannot differentiate recall rate according to age, therefore we counted all recalls as 36h DGNS-Report 2007 Page 21 of 49
22 13 cannot differentiate recall rate according to age, therefore we counted all recalls as 36h Biotinidase Deficiency 36h < 36h < 32WOG Recallrate Recall rate Recall rate Recall- Recall- Recall , , , , , , , , , , , , , , , Total , , , Galactosaemia 36h < 36h < 32WOG Lab Screenin Recall Recall Screenin Recallrate Recall g -rate Recall -rate Recall g , , , , , , , , , , , , , , , , , , , Total , , ,07 13 cannot differentiate recall rate according to age, therefore we counted all recalls as 36h DGNS-Report 2007 Page 22 of 49
23 13 cannot differentiate recall rate according to age, therefore we counted all recalls as 36h MS/MS Total 36h < 36h < 32WOG Recallrate Recall rate Recall rate Recall- Recall- Recall , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Total , , , PKU/HPA 36h < 36h < 32WOG Recallrate Recall rate Recall rate Recall- Recall- Recall , , , , , , , , , , , , , , , , , , , , , , , , Total , , ,43 13 cannot differentiate recall rate according to age, therefore we counted all recalls as 36h DGNS-Report 2007 Page 23 of 49
24 13 cannot differentiate recall rate according to age, therefore we counted all recalls as 36h MCAD-Deficiency < 32WOG MSUD 36h < 36h < 32WOG Recallrate Recall rate Recall rate Recall- Recall- Recall , , , , , , , , , , , , , , , , , Total , ,07 36h < 36h Recallrate Recall rate Recall Recall- Recall , , , , , , , , , , , , , , , Total , , Recallrate 13 cannot differentiate recall rate according to age, therefore we counted all recalls as 36h DGNS-Report 2007 Page 24 of 49
25 13 cannot differentiate recall rate according to age, therefore we counted all recalls as 36h LCHAD-Deficiency 36h < 36h < 32WOG Recallrate Recall rate Recall rate Recall- Recall- Recall , , , , , , , Total , , , VLCAD-Deficiency 36h < 36h < 32WOG Recallrate Recall rate Recall rate Recall- Recall- Recall , , , , , , , , , , , Total , , ,07 13 cannot differentiate recall rate according to age, therefore we counted all recalls as 36h DGNS-Report 2007 Page 25 of 49
26 13 cannot differentiate recall rate according to age, therefore we counted all recalls as 36h CPTII-Deficiency < 32WOG CPTI-Deficiency 36h < 36h < 32WOG Recallrate Recall rate Recall rate Recall- Recall- Recall , , Total , , ,04 36h < 36h Recallrate Recall rate Recall Recall- Recall Total , Recallrate 13 cannot differentiate recall rate according to age, therefore we counted all recalls as 36h DGNS-Report 2007 Page 26 of 49
27 13 cannot differentiate recall rate according to age, therefore we counted all recalls as 36h Glutaric acidaemia Type I 36h < 36h < 32WOG Recallrate Recall rate Recall rate Recall- Recall- Recall , , , , , , , , , Total , , , Isovaleric acidaemia 36h < 36h < 32WOG Recallrate Recall rate Recall rate Recall- Recall- Recall , , , , , , , , , , , , Total , ,2 13 cannot differentiate recall rate according to age, therefore we counted all recalls as 36h DGNS-Report 2007 Page 27 of 49
28 5 Process Periods 5.1 Age at blood collection According to the guidelines (Kinderrichtlinien, section 8, paragraph 1) the sampling should be performed between the 36 th and 72 nd hour of life. In 82,87% of cases, with specification of collection time, the collection was according to the guidelines, in 15,47% (5,81-25,41%) beyond the 72 nd hour of life, in 1,66% (0,9-4,36%) before the 36 th hour of life (see Table 5.1, figure 2). The number of cards with recorded times is less than the total number of first screening cards due to missing information on some cards (marked b in table 5.1). Although compared with the additional secondary screening cards, the numbers are higher. The 15.5% of samples taken beyond the 72nd hour of life are mainly first samples of children where the first screening was rejected. Table 5.1 Age at blood collection, primary screening Total <36h 36h-<48h 48h-<72h 72h Lab a n n % n % n % n % 1 b , , , ,20 3 b , , , ,81 5 c , , , , , , , ,14 8 b , , , , , , , , , , , ,13 11 b , , , ,85 12 b , , , ,23 13 b , , , , , , , , , , , ,79 Total , , , ,47 a 7 could not differentiate times and is therefore not listed. b and c see text Figure 2: Comparison: Age at blood collection 2005 to 2007 DGNS-Report 2007 Page 28 of 49
29 5.2 Period from sampling to laboratory receipt The time span between sampling and conveyance of suspect results should not exceed 72 hours (section 6, paragraph 3). In 20,35% (3,51-31,72%) of cases with statement of the delivery time the probe was received after 72 hours of sampling. In further 23,45% (9,87-31,69%) of the cases in a period between 48 and 72 hours. Shorter periods of delivery times are desirable, especially on the weekends. (Table 5.2) Table 5.2: Period between sampling and laboratory receipt Total 24h >24h-48h >48h-72h >72h Lab n n % n % n % n % 1 a , , , ,66 3 a , , , ,51 5 b , , , ,66 6 a , , , , , , , ,72 8 a , , , ,88 9 a , , , , , , , , , , , ,21 12 a , , , , , , , , , , , , , , , ,08 Total , , , ,35 Figure 3: Period between sampling and laboratory receipt: Comparison 2005 to Prozent < 24h 24-48h 48-72h >72h DGNS-Report 2007 Page 29 of 49
30 5.3 Period between laboratory receipt and conveyance Analysis of screening cards has to be done the same day of receipt. Pathological results then have to be reported promptly ( 14.3). Usually, this reporting is done via Telephone or Fax. This directive can only be achieved in 3 quarters of cases. Table 5.3 Period between laboratory receipt and conveyance Total 24h >24h-48h >48h-72h >72h Lab a n n % n % n % n % 1 b , , , ,36 3 b , , , , , , , , , , , ,94 9 b , , , , , , , , , , , ,84 12 b , , , , , , , , , , , , , , , ,54 Total , , , ,97 Figure 4: Period from laboratory receipt to conveyance, comparison of 2005 to Anteil der Proben (%) <24h 24-48h 48-72h > DGNS-Report 2007 Page 30 of 49
31 6 Time of screening in the confirmed cases. 6.1 screening Crucial for successful screening are the reliability of results and the promptness of further diagnostic evaluation and therapy in suspect cases. The optimal sampling time is the 48 th to the 72 nd hour of life ( 6.1). The probe should not be sampled before the 36 th and not after the 72 nd hour of life. The age of primary screening is shown for the targeted disease in Table 6.1. For clarity reasons the description >72 hours of age is reported in days. Exemplary the age of the children and the time of sampling, laboratory receipt, reporting and start of therapy are shown for children with hypothyroidism, CAH and PKU in figure 5, 6 and 7. Table 6.1 Time of primary screening in confirmed cases Disease 36-72h 4-7d >7d <36h <32WOG 36h, n.s. Time No information Hypothyroidism CAH Biotinidase Total Classic Galactosaemia PKU/HPA MSUD 2 2 MCAD LCHAD VLCAD CPT II 1 1 GA I IVA Total h n.s. does not include repeat testing with early sampling or preterm birth, but exact age of sampling time not stated. No information, neither WOG nor age at sampling. DGNS-Report 2007 Page 31 of 49
32 Figure 5: Time elapsed from initiation of therapy in children with hypothyroidism (n=129) Children whose treatment was initiated very late (with low TSH on primary screening), suffered from trisomy 21, were born <32 WOG or had sampling after blood transfusion. Figure 6: Time elapsed from initiation of therapy in children with CAH (n=44) Children that started late with therapy had 17 OHP values < 100nmol/l on screening DGNS-Report 2007 Page 32 of 49
33 Figure 7: Time elapsed from initiation of therapy in children with PKU (n=50) Days of life 6.2 Indication for request of repeat testing in the confirmed cases. An indication for a second screening could be early sampling before the 32 nd week of pregnancy or before the 36 th hour of life, even in children with confirmed diagnosis. In Table 6.2 the indications for repeat testing are shown Table 6.2 : Indication for request of repeat testing in the confirmed cases Indication for repeat screening Disease Recall < 36.h <32WOG No information Total Hypothyroidism CAH Biotinidase Classic Galactosaemia PKU/HPA MSUD 2 2 MCAD LCHAD VLCAD 8 8 CPTI 1 1 GA I 3 3 IVA 4 4 Total of 6 cases: TSH primary screening <20 mu/l; with n=1 suspicion of central hypothyroidism and n=1 after transfusion DGNS-Report 2007 Page 33 of 49
34 7 Confirmation of pathological results The following chapter outlines the diagnostic measures for confirmation of the suspected diagnosis as known to the laboratories. This information is used for quality control by the individual laboratories; unfortunately feedback by the Clinicians is not always warranted. For the year 2007 in 40 out of 465 confirmed cases no detailed information about the confirmation diagnostics is available, in a further 25 cases only limited information is given, that confirmation can not be accepted and we therefore do not list it in our analysis Hypothyroidism cases TSH T3 ft3 T4 ft4 ultrasound Thyroid antibodies n.s. n.s. n.s. 1 n.s. n.s n.s. n.s. 1 1 n.s n.s. 1 n.s. n.s. 4 n.s n.s n.s. 2 n.s n.s. n.s. n.s Total including n=8 cases without proper confirmation Congenital adrenal hyperplasia (CAH) cases 17-OHP (Serum) Serumsteroids Urinary steroids Molecular genetic testing n.s n.s. n.s. n.s n.s n.s. n.s. n.s n.s n.s n.s n.s. n.s. 2 Total including n=4 cases without proper confirmation DGNS-Report 2007 Page 34 of 49
35 7.1.3 Biotinidase deficiency cases Serum Biotinidase Molecular genetic testing n.s n.s. 6 1 n.s. n.s n.s n.s. Total including n=1 cases without proper confirmation Galactosaemia Classic cases Red cell GALT Molecular genetic testing n.s. 9 1 n.s. n.s n.s n.s. Total including n=1 cases without proper confirmation Galactosaemia inc. Variants cases Red cell GALT Molecular genetic testing n.s n.s. 9 2 n.s. n.s n.s n.s. Total including n=4 cases without proper confirmation DGNS-Report 2007 Page 35 of 49
36 7.1.5 PKU / HPA Lab cases Phe (Serum) Phe/Tyr BH4- Test BH4 sensitive Molecular genetic testing Pterine in Urine DHPR in dried blood n.s n.s. n.s. n.s. n.s n.s n.s n.s n.s. 1 n.s. n.s n.s. n.s. n.s Total including n=14 cases without proper confirmation MSUD cases Confirmation Serum Urinary organic acids Enzyme activity Molecular genetic testing n.s. n.s n.s. n.s. n.s. n.s. Total n.s. n.s. including n=9 cases without proper confirmation MCAD-Deficiency cases Confirmation Serum Urinary organic acids Enzyme activity Molecular genetic testing 1 5 n.s. 5 n.s n.s. n.s. n.s. n.s n.s n.s n.s n.s n.s n.s. 2 n.s n.s. n.s n.s. n.s n.s. n.s. 5 Total including n=9 cases without proper confirmation DGNS-Report 2007 Page 36 of 49
37 7.1.8 LCHAD-Deficiency cases Confirmation Serum Urinary organic acids Enzyme activity Molecular genetic testing n.s n.s. n.s. n.s. Total n.s VLCAD-Deficiency cases Confirmation Serum Urinary organic acids Enzyme activity Molecular genetic testing 1 1 n.s n.s. n.s n.s n.s. n.s. 1 n.s. Total CPT II-Deficiency cases Confirmation Serum Enzyme activity Molecular genetic testing 5 1 n.s. n.s Glutaric acidaemia Type I cases Confirmation Serum Urinary organic acids Enzyme activity Molecular genetic testing n.s n.s. 1 1 n.s. Total Isovaleric acidaemia cases Confirmation Serum Urinary organic acids Enzyme activity Molecular genetic testing n.s. n.s n.s. n.s. n.s n.s. n.s. n.s. n.s. Total n.s. n.s. including n=2 cases without proper confirmation DGNS-Report 2007 Page 37 of 49
38 8 Organisation 8.1 Acquisition of completeness Comparison with birth records 1 Yes 3 Yes 5 Yes 6 Yes Yes 11 Yes Name based Comparison with birth registry 12 Yes Yes 15 Total Tracking When necessary laboratories or regional screening centres do tracking in the listed situations. Suspicious < 36.Std. < 32 WOG Bad sample quality Confirmation Therapy Empty cards 1 Yes Yes Yes Yes Yes Yes 3 Yes Yes Yes Yes Yes Yes Yes 5 Yes Yes Yes Yes Yes Yes Yes 6 Yes Yes Yes Yes Yes Yes Yes 7 Yes Yes Yes Yes Yes 8 Yes Yes Yes Yes Yes 9 Yes Yes Yes Yes 10 Yes Yes Yes Yes Yes Yes Yes 11 Yes Yes Yes Yes Yes Yes Yes 12 Yes Yes Yes Yes Yes Yes Yes 13 Yes Yes Yes Yes Yes Yes Yes 14 Yes Yes Yes Yes Yes Yes Yes 15 Yes Yes Yes Yes Yes Yes DGNS-Report 2007 Page 38 of 49
39 9 Methods and cut offs in screening 9.1 Filter paper for sampling Filter paper 1 WS WS WS WS WS WS WS WS WS Macherey and Nagel Macherey and Nagel WS WS Hypothyroidism Parameter Cutoff [mu/l] Method 1 TSH 15 AutoDELFIA 3 TSH 15 AutoDELFIA 5 TSH n.s. AutoDELFIA 6 TSH 15 DELFIA 7 TSH 15 AutoDELFIA 8 TSH > 15 DELFIA 9 TSH 15 AutoDELFIA 10 TSH 15 AutoDELFIA 11 TSH 15 DELFIA 12 TSH >20 AutoDELFIA 13 TSH >20 AutoDELFIA 14 TSH > 20 AutoDELFIA 15 TSH > 20 AutoDELFIA DGNS-Report 2007 Page 39 of 49
40 9.3 Biotinidase Deficiency Parameter Cutoff Method 1 Biotinidase 30% board mean Colorimetrie qualitative 3 Biotinidase 30 % day mean Colorimetrie qualitative 5 Biotinidase n.s. Colorimetrie quantitative 6 Biotinidase 30% day mean Colorimetrie quantitative 7 Biotinidase 2,7 U/g Hb Colorimetrie quantitative 8 Biotinidase < 30% day mean Colorimetrie quantitative 9 Biotinidase 0,2 Colorimetrie qualitative 10 Biotinidase < 30% Colorimetrie qualitative 11 Biotinidase n.s. Colorimetrie qualitative 12 Biotinidase < 30% Fluorometrie quantitative 13 Biotinidase < 30% Fluorometrie quantitative 14 Biotinidase < 30 % Colorimetrie quantitative 15 Biotinidase < 30 % Colorimetrie quantitative 9.4 Galactosaemia Parameter Cutoff Method 1 GALT 3,5 U/gHb Fluorometrie(PE) Galactose 15 mg/dl BIORAD Quantase 3 GALT 2,3 Ug/Hb BIORAD Quantase Galactose 15 mg/dl 5 GALT Fluorometrie quantitative Galactose n.s. Colorimetrie quantitative 6 GALT 3,5 U/g Hb Fluorometrie quantitative 7 GALT 3,5 U/g Hb Fluorometrie quantitative GALT Galactose GALT Galactose GALT Galactose <20 % Tagesmittel >18 mg/dl (ab >30mg/dl) <2,3U/gHb 20 mg/dl 2,3U/gHb 1111μmol/l Fluoro quant non kit Colorimetrie non Kit BIORAD Quantase BIORAD Quantase BIORAD Quantase BIORAD Quantase 11 GALT 3,5 U/gHb Fluorometrie quantitative GALT Galactose GALT Galactose GALT Galactose GALT Galactose < 30% 15 mg/dl < 30% 15 mg/dl <2,3 U/g Hb >15mg/dl <2,3 U/g Hb >15mg/dl Fluoro. quant.(non-kit) Colorimetrie non Kit Fluoro. quant.(non-kit) Colorimetrie non Kit BIORAD Quantase BIORAD Quantase BIORAD Quantase BIORAD Quantase DGNS-Report 2007 Page 40 of 49
National. Screening Report 2008 DGNS
National Report 2008 DGNS Deutsche Gesellschaft für Neugeborenenscreening e.v. Dr. med. Uta Nennstiel-Ratzel MPH, Dr. med. Anja Lüders MPH, Dr. med. Oliver Blankenstein, Dr. rer. nat. Uta Ceglarek, Dr.
More informationNational. Screening Report 2005 DGNS
National Screening Report 2005 DGNS Dr. med. Uta Nennstiel-Ratzel MPH Dr. med. Oliver Blankenstein Dr. rer. nat. Uta Ceglarek Dr. rer. nat. Marina Stopsack Dr. rer. nat. Ralph Fingerhut Dr. med. Martin
More informationNational. Screening Report. Germany 2014
National Screening Report Germany 2014 German Society for Neonatal Screening (DGNS) Uta Nennstiel-Ratzel, Anja Lüders, Oliver Blankenstein, Uta Ceglarek, Regina Ensenauer, Gwendolyn Gramer, Jeannette Klein,
More informationNational. Screening Report. Germany 2016
National Screening Report Germany 2016 German Society for Neonatal Screening (DGNS) Uta Nennstiel, Anja Lüders, Oliver Blankenstein, Uta Ceglarek, Regina Ensenauer, Gwendolyn Gramer, Nils Janzen, Jeannette
More informationTitle: Assessing Recommendations Related To Timeliness of Newborn Screening
Title: Assessing Recommendations Related To Timeliness of Newborn Screening Purpose: In January 2014, the Secretary s Discretionary Advisory Committee on Heritable Diseases on Newborns and Children (Committee)
More informationERNDIM QA Scheme for qualitative blood spot acylcarnitine analysis. Annual Report 2010
UniversitätsKlinikum Heidelberg Universitätsklinik für Kinder- und Jugendmedizin Stoffwechselzentrum Heidelberg Stoffwechsellabor Im Neuenheimer Feld 430 69120 Heidelberg To Stoffwechselzentrum Heidelberg
More informationFor Your Baby s Health Department of Health
Newborn Screening For Your Baby s Health Department of Health Why is my baby tested? To help make sure your baby will be as healthy as possible. The blood test provides important information about your
More informationPositive Newborn Screens: What do you do next?
Positive Newborn Screens: What do you do next? James B. Gibson, MD, Ph.D. Biochemical Geneticist at Specially for Children Clinical Associate Professor of Pediatrics UTHSCSA Carla R. Scott, MD Pediatric
More informationRoutine Newborn Screening, Testing the Newborn Inherited Metabolic Disorders Update August 2015
Routine Newborn Screening, Testing the Newborn Inherited Metabolic Disorders Update August 2015 Metabolic birth defects can cause physical problems, mental retardation and, in some cases, death. It is
More informationNEWBORN METABOLIC SCREEN, MINNESOTA
Lab Dept: Test Name: Chemistry NEWBORN METABOLIC SCREEN, MINNESOTA General Information Lab Order Codes: Synonyms: CPT Codes: Test Includes: PKUN Newborn Screen for Hyopothyroidism, Phenylketonuria (PKU),
More informationOverview of Newborn Screening, Potential Uses of Residual Dried Blood Spots, and Protection of Privacy
Overview of Newborn Screening, Potential Uses of Residual Dried Blood Spots, and Protection of Privacy Alan R. Fleischman, M.D. Senior Vice President and Medical Director Chair, Federal Advisory Committee,
More informationAnnual Report Calendar Year 2015
Annual Report Calendar Year 2015 Page 1 of 19 Contents 1. SAMPLE VOLUMES IN 2015...3 1.1 SCREENING SAMPLES...3 1.1.1 INFANTS SCREENED...3 1.1.2 DECLINED/DEFERRED TESTING...4 1.1.3 MISSED SCREENS...5 1.2
More informationThe Compelling Benefits of Routine 2 nd NBS: A Fifteen-Year Review in Washington State. Saving lives with a simple blood spot
The Compelling Benefits of Routine 2 nd NBS: A Fifteen-Year Review in Washington State Caroline T. Nucup-Villaruz, MD Primary Author NBS Consultant - Disorder FU Santosh Shaunak Co-Author & Presenter Laboratory
More informationNewborn Screening in Manitoba. Information for Health Care Providers
Newborn Screening in Manitoba Information for Health Care Providers Newborn screening: a healthy start leads to a healthier life Health care professionals have provided newborn screening for phenylketonuria
More informationTIMELINESS OF NEWBORN SCREENING: RECOMMENDATIONS FROM ADVISORY COMMITTEE ON HERITABLE DISORDERS IN NEWBORNS AND CHILDREN
TIMELINESS OF NEWBORN SCREENING: RECOMMENDATIONS FROM ADVISORY COMMITTEE ON HERITABLE DISORDERS IN NEWBORNS AND CHILDREN Susan Tanksley, PhD May 19, 2015 TIMELINESS - BACKGROUND In order to effectively
More informationNewborn Screening: Focus on Treatment
Newborn Screening: Focus on Treatment Alan R. Fleischman, M.D. Senior Vice President and Medical Director March of Dimes National Conference of State Legislatures July 21, 2008 Newborn Screening: A Public
More informationFor the Ongoing Management of Babies under 1 year old.
Pathway Author: Nicy Turney, Senior Nurse Professional Lead, Health Visiting 19.06.17 For the Ongoing Management of Babies under 1 year old. Check Health Records (CHR) to undertake daily checks to identify:
More informationInformation for health professionals
Changes to the Newborn Bloodspot Screening Policy for Congenital Hypothyroidism (CHT) in Preterm Babies A UK policy change has been agreed that will mean changes to: which preterm babies require second
More informationNewborn Bloodspot Screening Information for parents
Newborn Bloodspot Screening Information for parents You will be offered a bloodspot screening test for your newborn baby for several rare but serious conditions. The sample for this test is usually taken
More informationAttachment 1. Newborn Screening Program Description
Attachment 1 Newborn Screening Program Description The core mission of Texas Newborn Screening Program is to save children s lives through the early detection of life-threatening disorders. 34 Newborn
More informationNewborn Bloodspot Screening Information for parents
Newborn Bloodspot Screening Information for parents You will be offered a bloodspot screening test for your newborn baby for several rare but serious conditions. The sample for this test is usually taken
More informationNewborn Metabolic Screening Programme Annual Report
Newborn Metabolic Screening Programme Annual Report January to December 2015 Disclaimer This publication reports on information provided to the Ministry of Health by the Auckland District Health Board.
More informationERNDIM QA Scheme for qualitative urinary organic acid analysis. Annual Report 2010
UniversitätsKlinikum Heidelberg Universitätsklinik für Kinder- und Jugendmedizin Stoffwechselzentrum Heidelberg Stoffwechsellabor Im Neuenheimer Feld 430 69120 Heidelberg To Stoffwechselzentrum Heidelberg
More informationNewborn Screening in Washington State Saving lives with a simple blood spot
Newborn Screening in Washington State Saving lives with a simple blood spot Ashleigh Ragsdale, MPH Gauri Gupta, MScPH Objectives Newborn Screening Overview Process and Law Completing Collection Cards Video
More informationNewborn Metabolic Screening Programme
Newborn Metabolic Screening Programme Annual Report January to December 2017 Released 2018 health.govt.nz Disclaimer This publication reports on information provided to the Ministry of Health by the Auckland
More informationAnnual Report Calendar Year 2014
Annual Report Calendar Year 2014 1 Contents 1. SAMPLE VOLUMES IN 2014...4 1.1 SCREENING SAMPLES...4 1.1.1 INFANTS SCREENED...4 1.1.2 DECLINED/DEFERRED TESTING...5 1.1.3 MISSED SCREENS...6 1.2 NON-SCREENING
More informationNewborn Metabolic Screening Programme. Annual Report
Newborn Metabolic Screening Programme Annual Report January to December 2016 1 Disclaimer This publication reports on information provided to the Ministry of Health by the Auckland District Health Board.
More informationERNDIM QA Scheme for Qualitative Blood Spot Acylcarnitine Analysis. Annual Report 2011
UniversitätsKlinikum Heidelberg University Children s Hospital Metabolic Laboratory Im Neuenheimer Feld 430 69120 Heidelberg To University Children s Hospital Angelika-Lautenschläger-Klinik Department
More informationNEWBORN SCREENING. in Massachusetts: Answers for You and Your Baby. University of Massachusetts Medical School
University of Massachusetts Medical School NEWBORN SCREENING in Massachusetts: Answers for You and Your Baby New England Newborn Screening Program Biotech 4, 2nd Floor UMass Medical School 377 Plantation
More informationInborn Errors of Metabolism From Neonatal Screening to Metabolic Pathways
19 May 2015 Hospital Authority Convention 2015 Corporate Scholarship Presentation II Paediatric Services Inborn Errors of Metabolism From Neonatal Screening to Metabolic Pathways Dr Grace Poon Associate
More informationNewborn Screening & Methods for Diagnosing Inborn Errors of Metabolism
Newborn Screening & Methods for Diagnosing Inborn Errors of Metabolism Patricia Jones, PhD DABCC FACB UT Southwestern Medical Center Children s Medical Center Dallas, Texas Learning Objectives Justify
More information(f) "Birthing center" means any facility that is licensed by the Georgia Department of Community Health as a birthing center;
Ga. Comp. R. & Regs. r. 511-5-5-.02 Definitions Rule 511-5-5-.02. Definitions (a) "Abnormal test result" is a test result from blood testing or physiologic monitoring that is outside the screening limits
More informationMost common is the congenital adrenogenital syndrome (AGS) or congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.
Newborn Screening Examination parameters: TSH-neonatal (hypothyreosis), 17-OH progesterone (AGS), galactose (galactosemia), galactose-uridyl transferase (galacto semia), biotinidase (biotinidase ), phenylalanine
More informationSlide 1: Newborn Bloodspot Screening for Medium-chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Slide 1: Newborn Bloodspot Screening for Medium-chain Acyl-CoA Dehydrogenase Deficiency (MCADD) The information has been produced with thanks to the NHS Newborn Blood Spot Screening Programme. 1 Slide
More informationNewborn screening for additional metabolic diseases using second-tier strategies Juergen G. Okun, PhD
Newborn screening for additional metabolic diseases using second-tier strategies Juergen G. Okun, PhD 5th EFLM-UEMS European Joint Congress in Laboratory Medicine 10-13 October 2018 in Antalya, Turkey
More information[R23-13-MET/HRG] STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS DEPARTMENT OF HEALTH. February October October 1992 (E) September 1995
RULES AND REGULATIONS PERTAINING TO THE NEWBORN METABOLIC, ENDOCRINE, AND HEMOGLOBINOPATHY SCREENING PROGRAM AND THE NEWBORN HEARING LOSS SCREENING PROGRAM [R23-13-MET/HRG] STATE OF RHODE ISLAND AND PROVIDENCE
More informationNewborn Screening: Blood Spot Disorders
Newborn Screening: Blood Spot Disorders Arizona s Newborn Screening Program Program Overview Panel of Disorders Disorder Descriptions Program Components Hospitals ADHS Lab ADHS Follow-up ADHS Billing Medical
More informationSUNY Downstate Medical Center -University Hospital of Brooklyn Network Department of Pathology Policy and Procedure
SUNY Downstate Medical Center -University Hospital of Brooklyn Network Department of Pathology Policy and Procedure Subject: NEWBORN SCREENING FOR METABOLIC DEFICIENCIES Prepared By: Yolaine Henry Edit
More informationSaving Lives Through Newborn Screening: Making the Most of a Simple Blood Test
Saving Lives Through Newborn Screening: Making the Most of a Simple Blood Test February 26, 2018 John D. Thompson, PhD, MPH, MPA Director - NBS Program Washington State Public Health Laboratories What
More informationNewborn Bloodspot Screening (NBS) Training for Health Visitors. December 2017
Newborn Bloodspot Screening (NBS) Training for Health Visitors www.newbornbloodspotscreening.wales.nhs.uk December 2017 Aims To enable you to gain a clear understanding of the following: Aim and rationale
More informationAnnual Report 2015 (updated version)
UniversitätsKlinikum Heidelberg Universitätsklinik für Kinder- und Jugendmedizin Stoffwechselzentrum Heidelberg Stoffwechsellabor Im Neuenheimer Feld 669 69120 Heidelberg To University Children s Hospital
More informationComprehensive cost-utility analysis of newborn screening strategies Carroll A E, Downs S M
Comprehensive cost-utility analysis of newborn screening strategies Carroll A E, Downs S M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS
More informationActivities in the field of rare diseases in Slovakia. CISARIK František Faculty Hospital Žilina
Activities in the field of rare diseases in Slovakia CISARIK František Faculty Hospital Žilina As we progress? Slovak National Strategy for the Development of Health Care for Patients with Rare Diseases
More informationHow MS/MS Revolutionized Newborn Screening
How MS/MS Revolutionized Newborn Screening David S Millington, PhD Medical Research Professor of Pediatrics Director, Biochemical Genetics Laboratory Duke University Medical Center NEWBORN SCREENING IN
More informationAnnual Report Zurich 2017 Date of issue: 19 th April 2018 Amended report issued: 1 st May
ERNDIM Administration Office Manchester Centre for Genomic Medicine 6 th Floor, St Mary's Hospital, Oxford Road, Manchester M13 9WL, United Kingdom. Tel: +44 161 276 6741 Fax: +44 161 850 1145 Email: admin@erndim.org
More informationFlow of samples and information for newborn screening in a model of publicprivate
Flow of samples and information for newborn screening in a model of publicprivate partnership Marzia Pasquali, PhD, FACMG Associate Professor of Pathology, University of Utah Medical Director, Biochemical
More informationBeyond the case for NBS in South Africa. Chris Vorster 28/05/2016
Beyond the case for NBS in South Africa Chris Vorster 28/05/2016 The case for NBS in SA Economic justification Cost Utility analysis = Cost/QALY GDP/Capita Immediate implementation (WHO) Political justification
More informationMISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES
NEWBORN SCREENING Protecting your newborn MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES [ 1 ] NEWBORN SCREENING [ 2 ] FREQUENTLY ASKED QUESTIONS [ 4 ] DISORDERS INCLUDED IN NEWBORN SCREENING [ 12 ]
More informationHA Convention 2016 Master course How to Handle Abnormal Newborn Metabolic Screening Results Causes, Management and Follow up
HA Convention 2016 Master course How to Handle Abnormal Newborn Metabolic Screening Results Causes, Management and Follow up Dr. Josephine Chong Clinical Professional Consultant Centre of Inborn Errors
More informationNewborn bloodspot testing
Policy HUMAN GENETICS SOCIETY OF AUSTRALASIA ARBN. 076 130 937 (Incorporated Under the Associations Incorporation Act) The liability of members is limited RACP, 145 Macquarie Street, Sydney NSW 2000, Australia
More informationAnnual Report to the Newborn Screening Ontario Advisory Council Calendar Year 2017
Annual Report to the Newborn Screening Ontario Advisory Council Calendar Year 2017 415 Smyth Road, Ottawa Ontario K1H 8M8 Phone: 6137383222 1877NBS8330 Fax: 6137380853 Contents 1. SAMPLE VOLUMES IN 2017...4
More informationAnalytes, instrumentation and software for neonatal screening. Complete solutions for screening newborns
Analytes, instrumentation and software for neonatal screening Complete solutions for screening newborns w w w. p e r k i n e l m e r. c o m 1 Everything you need for efficient neonatal screening PerkinElmer
More informationFurther expansion of the neonatal screening panel in the Netherlands
Further expansion of the neonatal screening panel in the Netherlands J.Gerard Loeber APHL-NBSGT, St.Louis (MO), USA 290216 Population Area Newborns 6.01 million 0.35:1 16.8 million 180,693 sq km 4.3:1
More informationA Guide for Prenatal Educators
A Guide for Prenatal Educators Why Teach Newborn Screening This booklet is designed to make it easy for you, a prenatal educator, to effectively inform expectant parents about newborn screening. All of
More informationNEWBORN SCREENING. in Massachusetts: Information for You and Your Baby. University of Massachusetts Medical School
University of Massachusetts Medical School NEWBORN SCREENING in Massachusetts: Information for You and Your Baby New England Newborn Screening Program Biotech 4, 2nd Floor UMass Medical School 377 Plantation
More informationPilot Study of Newborn Screening (NBS) for Inborn Errors of Metabolism (IEM) in Collaboration with Department of Health and Hospital Authority
HA Convention 2017 Service Enhancement Presentation Healthcare Advances, Research and Innovations Pilot Study of Newborn Screening (NBS) for Inborn Errors of Metabolism (IEM) in Collaboration with Department
More informationQA/QC 2 Strategies to Reduce False Positives and False Negatives (Part 2)
QA/QC 2 Strategies to Reduce False Positives and False Negatives (Part 2) Tuesday, Oct. 28 10:30am-12:00pm Moderators Patricia Hunt, Texas Department of State Health Services and Bob Currier, California
More informationNEWBORN SCREENING. health.mo.gov/newbornscreening MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES
NEWBORN SCREENING health.mo.gov/newbornscreening MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES Table of Contents NEWBORN SCREENING...1 FREQUENTLY ASKED QUESTIONS...2 DISORDERS INCLUDED IN NEWBORN SCREENING...4
More informationSending and Receiving Newborn Screening Results in Indiana: The HIE Perspective
Sending and Receiving Newborn Screening Results in Indiana: The HIE Perspective Shaun Grannis, MD, MS FAAFP, Regenstrief Bob Bowman, MS, MA, MS, ISDH Nov 2, 2010 What we ll cover Health Information Exchange
More informationAssessing Mothers Knowledge of the Wisconsin Newborn Screening Program. Sara Wolfgram UW Master of Public Health Symposium August 11, 2006
Assessing Mothers Knowledge of the Wisconsin Newborn Screening Program Sara Wolfgram UW Master of Public Health Symposium August 11, 2006 Background Wisconsin Newborn Screening (NBS): Began in 1965 Heel
More informationPost mortem investigation of Inherited Metabolic Disease - the last opportunity for a diagnosis -
Post mortem investigation of Inherited Metabolic Disease - the last opportunity for a diagnosis - Dr Simon Olpin Lead Clinical Scientist in Inherited Metabolic Disease Sheffield Children s Hospital SIDS/SUDI
More informationScreening Division of Public Health Wales NBSW Annual Statistical Report 2017/18
` Date: November 2018 Version: 1 Page: 1 of 29 Date: November 2018 Version: 1 Page: 2 of 29 The report is only available electronically from the screening programme and will be available on the website:
More informationSo Much More Than The PKU Test
Newborn Metabolic Screening So Much More Than The PKU Test Sarah Viall, MSN, PPCNP BC Newborn Screening Program Coordinator Division of Genetics & Metabolism Conflicts of Interest I have no conflicts of
More informationScreening Newborns for Congenital Disorders
Screening Newborns for Congenital Disorders Gary L. Hoffman, BS; Ronald H. Laessig, PhD ABSTRACT The Newborn Screening Laboratory at the Wisconsin State Laboratory of Hygiene (WSLH) tests all newborn babies
More informationNewborn Screening in Japan: Restructuring for the New Era
Plenary 13 Newborn Screening in Japan: Restructuring for the New Era Seiji Yamaguchi, 1 MD Abstract Nationwide neonatal mass screening for inherited metabolic diseases has started in Japan since 1977.
More informationNewborn Genetic Testing & Surveillance System
Georgia Newborn Genetic Testing & Surveillance System State GA Statute/ Rule STATUTE: Chapter 1 Chapter 2 Chapter 12 Title 33 Chapter 54 RULE: 290-5-.02 and 290-5- 24 Language Specific to Genetic Testing
More informationJoshua Hellmann Foundation Newborn Metabolic Screening Program Clinical Protocol
Joshua Hellmann Foundation Newborn Metabolic Screening Program Clinical Protocol Centre of Inborn Errors of Metabolism The Chinese University of Hong Kong Version 7 Effective Date: 15 th February 2016
More informationNewborn Screening: What s New?
Newborn Screening: What s New? Patricia M. Jones, PhD (Department of Pathology, University of Texas Southwestern Medical Center and Children s Medical Center of Dallas, Dallas, TX) DOI: 10.1309/LMOOXWVPSM5FC3B6
More information2015 Annual Report for New Mexico s Newborn Screening (NBS) Program
2015 Annual Report for New Mexico s Newborn Screening (NBS) Program Sawyer-A Family s Story Inside this Edition A Family Story......1 Why Screen....4 When to Screen...4 What is NBS....5 Screened Conditions..5
More informationLab Guide 2019 Metabolic Section Lab Guide
Lab Guide 2019 Metabolic Section Lab Guide Quantitative Amino acids Plasma Plasma. Container/Tube: Preferred EDTA, Place immediately in ice. Acceptable: lithium heparin, sodium heparin. Patient preparation:
More informationNewborn Metabolic Screening Programme. Annual Report
Newborn Metabolic Screening Programme Annual Report January to December 2014 Copyright The copyright owner of this publication is the Ministry of Health, which is part of the New Zealand Crown. The Ministry
More informationERNDIM QA Scheme for qualitative urinary organic acid analysis. Annual Report 2011
UniversitätsKlinikum Heidelberg Universitätsklinik für Kinder- und Jugendmedizin Stoffwechselzentrum Heidelberg Stoffwechsellabor Im Neuenheimer Feld 430 69120 Heidelberg To Stoffwechselzentrum Heidelberg
More informationPast, present and future of newborn screening in Chile
DOI 10.1007/s10545-010-9165-8 RESEARCH REPORT Past, present and future of newborn screening in Chile V. Cornejo & E. Raimann & J. F. Cabello & A. Valiente & C. Becerra & M. Opazo & M. Colombo Received:
More informationCOMMON INHERITED METABOLIC CONDITIONS IN SOUTH AFRICA DIAGNOSING RARE DISEASE IN GENETICALLY UNIQUE AND UNDERSTUDIED POPULATION GROUPS
COMMON INHERITED METABOLIC CONDITIONS IN SOUTH AFRICA DIAGNOSING RARE DISEASE IN GENETICALLY UNIQUE AND UNDERSTUDIED POPULATION GROUPS S MELDAU, G VAN DER WATT INHERITED METABOLIC DISEASES GROUP UCT /
More informationSabrina Schmitt: "German Biobank Node s concept for quality management"
Sabrina Schmitt: "German Biobank Node s concept for quality management" German Biobank Node s concept for quality management S. Schmitt K.-F. Becker, B. Meinung, E. Herpel, J. Slotta-Huspenina Sep-14-2016,
More informationAssessing the follow-up of BART hemoglobin reported by the Wisconsin Newborn Screening Laboratory
Assessing the follow-up of BART hemoglobin reported by the Wisconsin Newborn Screening Laboratory Bao Yang MPH Candidate Background The Wisconsin Newborn Screening (NBS) Laboratory screens 70,000 babies
More informationState of the Art of Rare Disease - Activities in EU Member States and Other European Countries. Portugal Report
State of the Art of Rare Disease - Activities in EU Member States and Other European Countries Definition of a Rare Disease Portugal Report Portugal has adopted the European Commission definition of a
More informationHealth and Wellness for all Arizonans. azdhs.gov
To identify newborns with certain, rare disorders and assist families of affected infants so that they receive appropriate and timely treatment to prevent or delay serious medical problems. To identify
More informationInborn Errors of Metabolism. Metabolic Pathway. Digestion and Fasting. How is Expanded Newborn Screening Different? MS/MS. The body is a factory.
Inborn Errors of Metabolism The body is a factory. Inborn errors of metabolism are rare genetic disorders in which the body cannot properly turn food into energy. The disorders are usually caused by defects
More informationMost common metabolic disorders in childhood. Neonatal screening and diagnostic approach to the. Inborn errors of metabolism (IEM)
Department of Pediatrics and Developmental Disorders Medical University of Bialystok Most common metabolic disorders in childhood. Neonatal screening and diagnostic approach to the inborn errors of metabolism
More informationPractitioner s Manual
New Mexico Practitioner s Manual The New Mexico Practitioner s Manual New Mexico Department of Health Children s Medical Services Newborn Screening Program Brenda Romero, RN, BSN Carla Ortiz, RN, BSN Elizabeth
More informationNEWBORN SCREENING IN JAPAN
NEWBORN SCREENING IN JAPAN Kikurnaro Aoki KagawaNutrition University, Saitama, Japan Abstract. In the 19701s, the government began to take steps for the treatment of congenital diseases. Mass newborn screening
More informationProposal for EXPANDED NEWBORN SCREENING
Proposal for EXPANDED NEWBORN SCREENING Tel:+971-4-4503875 Fax:+971-4-4503874 DuBiotech, P.O.Box 212671Dubai, UAE. Email: info@easternbiotech.com www.easternbiotech.com Winner of Dubai SME100 Ranked #19
More informationValidation of MCADD newborn screening
Clin Genet 2009: 76: 179 187 Printed in Singapore. All rights reserved Short Report 2009 John Wiley & Sons A/S CLINICAL GENETICS doi: 10.1111/j.1399-0004.2009.01217.x Validation of MCADD newborn screening
More informationGreen Amber Red Assurance Level
A re-audit of the turnaround time of samples for the Sickle Cell and Thalassaemia Newborn Screening Programme, in the Manchester Newborn Screening Laboratory Clinical Audit Report May 2014 Clinical Audit
More informationNEONATAL SCREENING FOR INBORN ERRORS OF METABOLISM OUR EXPERIENCE AT CABRI, GULF MEDICAL UNIVERSITY
GMJ GULF MEDICAL JOURNAL ORAL PROCEEDINGS NEONATAL SCREENING FOR INBORN ERRORS OF METABOLISM OUR EXPERIENCE AT CABRI, GULF MEDICAL UNIVERSITY I.A. Shaafie 1 *, A.D. Vijay Raju 2, P.K. Menon 3 1Division
More informationInformation for health professionals
Introduction of a new screening test for newborn babies in Wales Newborn bloodspot screening for Medium chain acyl-coa dehydrogenase deficiency (MCADD) Newborn bloodspot screening for MCADD is being introduced
More informationNewborn Screening. Helping babies start life healthy. Minnesota Newborn Screening Program
Newborn Screening Helping babies start life healthy Minnesota Newborn Screening Program What is newborn screening? Newborn screening is a set of three tests that check babies for serious, rare conditions.
More informationMitochondrial Fatty Acid Oxidation Deficiencies Prof. Niels Gregersen
Mitochondrial Fatty Acid Oxidation Deficiencies Research Unit for Molecular Medicine Clinical Institute Aarhus University Hospital and Faculty of Health Sciences Aarhus University, Aarhus, Denmark 1 Menu
More informationSelective newborn screening of amino acid, fatty acid and organic acid disorders in the Kingdom of Bahrain.
Selective newborn screening of amino acid, fatty acid and organic acid disorders in the Kingdom of Bahrain. Jamal Golbahar PhD Associate Professor of Molecular Medicine, Department of Molecular Medicine,
More informationCongenital Hypothyroidism Referral Guidelines for Newborn Bloodspot Screening Wales
Congenital Hypothyroidism Referral Guidelines for Newborn Bloodspot Screening Wales September 2014 Version 1 Based on the CHT initial Clinical Referral Standards and Guidelines in the UK [www.newbornbloodspot.screening.nhs.uk/cht]
More informationBiochemical Genetics
Biochemical Genetics Laboratory Handbook 20010/11 Block 20 St James s Hospital Beckett Street Leeds LS9 7TF Introduction The Biochemical Genetics service is comprised of two regional laboratories, screening
More informationNATIONAL PROTOCOLS. Newborn Bloodspot Screening Programme. Release: Version 1.0. Date: Feb 2017
keppåçíä~åç=påêééåáåö=mêçöê~ããéë=j=mêéöå~ååó=~åç=kéïäçêå=påêééåáåö= NATIONAL PROTOCOLS Programme: Newborn Bloodspot Screening Programme Release: Version 1.0 Date: Feb 2017 CONTENTS Foreword 4 Key points
More informationSCAD and GA-II: Truths and Confusions
SCAD and GA-II: Truths and Confusions Bill Rhead* Medical College of Wisconsin *MD, PhD GA-II Severe GA-II is as bad as: SCAD + MCAD + COMBINED! VLCAD + IVA + GA-I Severe GA-II is always fatal Mild
More informationNewborn Screening and Studies of Lysosomal Storage Diseases in CFOH
Newborn Screening and Studies of Lysosomal Storage Diseases in CFOH Chinese Foundation of Health National Yang-Ming University Director: Dr. Chuan-Chi Chiang Speaker: Hsuan-Chieh Liao (Joyce) 1 Newborn
More informationNewborn screening project at departments of genetics and endocrinology SGPGIMS, Lucknow
Newborn screening project at departments of genetics and endocrinology SGPGIMS, Lucknow Population based newborn screening (NBS) is being carried out in developed nations for the last 40 years. It aims
More informationAuthor's personal copy
Author's personal copy J Inherit Metab Dis DOI 10.1007/s10545-012-9483-0 SSIEM SYMPOSIUM 2011 Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1 - From blood
More informationA Pilot Study on an Expanded Newborn Screening Program in Palestine. Phaseп
A Pilot Study on an Expanded Newborn Screening Program in Palestine. Phaseп Genetics and Metabolic Diseases Center Faculty of Medicine/Al-Quds University Samir Khatib, PhD Amer Ayyad,MSc Outline 1- Background
More informationGUIDE TO NEWBORN SCREENING PROGRAMME
\ GUIDE TO NEWBORN SCREENING PROGRAMME 1 MEDILAB PROFILE MEDILAB, the leading independent provider of Clinical Laboratory Diagnostic Services in Cyprus, was established in 1980 by Mr. C. Pavlides and has
More informationThe spectrum and outcome of the. neonates with inborn errors of. metabolism at a tertiary care hospital
The spectrum and outcome of the neonates with inborn errors of metabolism at a tertiary care hospital Dr. Sevim Ünal Neonatology Division, Ankara Children s Hematology Oncology Research Hospital, Ankara,
More information